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ABSTRACT
Objective To determine whether fluoroscopic guidance
improves outcomes of injections for greater trochanteric
pain syndrome.
Design Multicentre double blind randomised controlled
study.
SettingThreeacademicandmilitarytreatmentfacilitiesin
the United States and Germany.
Participants 65 patients with a clinical diagnosis of
greater trochanteric pain syndrome.
Interventions Injections of corticosteroid and local
anaestheticintothetrochantericbursa,usingfluoroscopy
(n=32) or landmarks (that is, “blind” injections; n=33) for
guidance.
Main outcome measures Primary outcome measures: 0-
10 numerical rating scale pain scores at rest and with
activity at one month (positive categorical outcome
predefined as ≥50% pain reduction either at rest or with
activity, coupled with positive global perceived effect).
Secondary outcome measures included Oswestry
disabilityscores,SF-36scores,reductionindruguse,and
patients’ satisfaction.
Results No differences in outcomes occurred favouring
either the fluoroscopy or blind treatment groups. One
month after injection the average pain scores were 2.7 at
rest and 5.0 with activity in the fluoroscopy group
compared with 2.2 and 4.0 in the blind injection group.
Three months after the injection,15 (47%) patientsin the
blind group and 13 (41%) in the fluoroscopy group
continued to have a positive outcome.
Conclusion Although using fluoroscopic guidance
dramatically increases treatment costs for greater
trochanteric pain syndrome, it does not necessarily
improve outcomes.
Trial registration Clinical trials NCT00480675
INTRODUCTION
Rapidadvancementsinelucidatingthemechanismsof
disease, preventive and diagnostic capabilities, and
therapeutic interventions have not necessarily been
reflected in better treatment outcomes. Nowhere is
thisincongruitymoreevidentthaninthemanagement
of pain. Although the field of pain management has
seen a dramatic surge in recognition, research interest,
resourceallocation, and treatmentoptions,the rates of
painrelateddisabilitycontinuetosoar.
12Thisdisparity
has led some experts to question the relations between
scientific advancements, expenditures, and quality of
health care.
34
Greater trochanteric pain syndrome, also known as
trochanteric bursitis, is a common medical condition
with a lifetime prevalence exceeding 20%; it occurs
more frequently in women, older people, and people
with low back pain.
5-9 Corticosteroid injections can
provide considerable relief in most patients who fail
to respond to conservative treatment.
610-13 One epide-
miological study in a primary care setting found that
patients who received a corticosteroid injection had a
2.7-fold greater chance of long term recovery com-
pared with patients who had not had an injection.
14
Despite the prevalence of greater trochanteric pain
syndrome, onlya few studiesevaluatingthe efficacy of
corticosteroid injections have been published, none of
whichwascontrolledorusedfluoroscopyorotherima-
ging techniques (such as ultrasonography). The aver-
age success rate in these studies ranged between 50%
and 70%, with follow-up ranging between two weeks
and two years.
810111516 Because many studies have
shown that fluoroscopic guidance is necessary to
ensure correct placement of the needle during many
interventional pain treatments,
17-22 an observational
study sought to determine the accuracy of “blind” tro-
chantericbursainjections.
23Intra-bursalspreadofcon-
trast occurred in only 45% of landmark guided
trochanteric bursa injections, and the authors con-
cluded that fluoroscopic guidance is necessary to
ensureplacementoftheneedlewithinthebursa.How-
ever, this study did not assess outcomes.
In order to determine whether fluoroscopy should
be routinely used during trochanteric bursa cortico-
steroid injections, we did a multicentre, randomised
controlled study comparing fluoroscopically guided
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reasons. Firstly, greater trochanteric pain syndrome is
a clinical diagnosis, but recent studies have shown that
onlyasmallpercentageofpatientswhomeetinclusion
criteria for greater trochanteric pain syndrome have
radiological evidence of bursal inflammation.
2425
Extra-bursal hip injections might therefore be as effec-
tive as, or even superior to, intra-bursal trochanteric
injections. Secondly, giving any injection under radio-
graphic guidance usually requires pain management
services. This adds to the cost of treatment, and the
delays inherent in obtaining subspecialty care can
impair outcomes of treatment.
26-28
METHODS
The trial took place between January 2007 and March
2008 at Johns Hopkins Medical Institutions, Walter
Reed Army Medical Center, and Landstuhl Regional
Medical Center, a US military treatment facility oper-
ating in Landstuhl, Germany. A two tailed power ana-
lysis determined that a sample size of 64 had 90%
power to detect a 1.5 point difference in the 0-10
numerical rating scale pain scores between groups at
a significance level (α) of 0.05.
Allprocedurestookplaceinapainclinicinanambu-
latory care setting; superficial anaesthesia was used.
Inclusion criteria included pain of more than three
months’ duration, spontaneous pain in the lateral
aspect of the hip, tenderness overlying the greater tro-
chanter,andoneofthefollowingthreeminordiagnos-
tic criteria: increased pain with extremes of rotation,
abduction, or adduction; pain with forced hip abduc-
tion;andpseudoradicularpainextendingdownthelat-
eralaspectofthethigh.Exclusioncriteriaincludedage
under 18 years, trochanteric bursa injection within the
previous nine months, coagulopathy, allergy to con-
trast dye, and unstable medical or psychiatric condi-
tion that might preclude an optimal treatment
response.
Randomisation and treatment
A physician not involved in randomisation enrolled
and treated all participants. Participants were rando-
mised in a 1:1 ratio to receive either fluoroscopically
guided or landmark guided (that is, “blind”) trochan-
tericbursainjections.Aresearchnursenot involvedin
patient care randomised participants in blocks of four
viapre-sealedenvelopesatJohnsHopkinsandthetwo
military institutions, which we considered as a single
entity. Patients were placed in the lateral position
with the affected side up, after which the most tender
area was marked over the anticipated site of the bursa.
A “sham” cross table antero-posterior image of the
femurwastakentofacilitateblinding.Usingonlyland-
markstoguideneedleinsertion,thephysicianinserted
a 22 gauge 3.5 inch spinal needle into the suspected
bursa. The physician then injected 0.5 ml of contrast
and took a true antero-posterior image to determine
whether the contrast was within one of the subgluteus
maximus or subgluteus medius trochanteric bursas. In
those patients randomised to the “blind injection”
group, the physician injected a 4 ml solution contain-
ing 60 mg of depo-methylprednisolone and 2.5 ml of
0.5% bupivacaine regardless of whether the contrast
entered the bursa. For patients in the fluoroscopy
group, the same solution was injected only if the
image revealed intra-bursal spread. If the injection
wasextra-bursal,thephysicianthenreadjustedthenee-
dle and repeated the process until intra-bursal spread
of contrast was confirmed, at which point the injectate
was administered. At the conclusion of the procedure,
Potential study participants with trochanteric bursitis (n=79)
Randomised (n=65)
Fluoroscopically guided trochanteric
bursa injections, all intra-bursal (n=32)
“Blind” trochanteric bursa injections (n=33)
Successful outcome at 3 months (n=15) Successful outcome at 3 months (n=13)
Completed (n=32)
Dropouts (n=0)
Completed (n=32)
Dropouts (n=1)
Intra-bursal (n=11) Extra-bursal (n= 21)
Successful outcome 
at 1 month (n=22)
Excluded (n=14):
  Logistical reasons (pending overseas deployment) (n=3)
  Inability to successfully treat primary pain complaint (n=4)
  Dementia (n=1)
  Refused participation (n=6)
Exited study at
1 month secondary
to negative outcome
(n=15)
Exited study at
1 month secondary
to negative outcome
(n=10)
Successful outcome 
at 1 month (n=17)
Flow of participants through study
Table 1 |Baseline demographic and clinical characteristics by study centre. Values are
numbers (percentages) unless stated otherwise
Characteristics
Johns Hopkins
(n=36)
Walter Reed
(n=20)
Landstuhl
(n=9) P value
Mean (SD, range) age (years) 57.9(12.6,30-85) 59.1(11.9,34-79) 35.4(10.5,21-53) <0.0001
Female sex 32 (89) 19 (95) 5 (56) 0.02
Obesity 8 (22) 8 (40) 1 (11) 0.21
Mean (SD, range) duration of pain
(years)
4.1 (4.2, 0.1-16) 3.1 (2.4, 0.1-7.5) 4.8 (3.5, 0.3-10) 0.49
Opioid use 15 (42) 5 (25) 2 (22) 0.41
Mean (SD, range) Oswestry
disability index score
43.3(13.1,18-67) 36.8(14.9,14-62) 37.2(12.5,20-54) 0.18
Mean (SD, range) pain intensity at
rest*
5.5 (5.0, 1-10) 4.2 (2.4, 1-9) 3.6 (1.2, 2-6) 0.06
Mean(SD,range)painintensitywith
activity*
8.0 (1.9, 3-10) 7.1 (2.3, 2-10) 6.4 (1.4, 3.5-8) 0.07
Success: (n=35) (n=20) (n=9)
0.49
None 11 (31) 11 (55) 3 (33)
At 1 month only 7 (20) 3 (15) 1 (11)
At 3 months 17 (49) 6 (30) 5 (56)
*Numerical rating pain scale.
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Outcome measures and follow-up
A physician unaware of the patient’s study group
assignment obtained all outcome data during sched-
uled follow-up visits. Between the procedure and first
follow-up, we permitted no contact between any
patient and investigator. All patients were seen in the
treating clinic one month after the procedure. If a
patient had a positive global perceived effect and sig-
nificant (≥50%) pain relief obviating the need for
further treatment, he or she was re-evaluated three
months post-treatment. Patients who did not have
adequate pain relief one month after the procedure
wereunblindedandleftthestudytoreceivealternative
medical care. Therationale for thisdecision was based
on pilot data showing that only 7% of patients who
failed to experience relief one month after a trochan-
tericbursainjectionhadapositiveoutcome8-12weeks
post-procedurewithnointerveningtreatment.Patients
who continued to receive satisfactory pain relief were
unblinded after their final three month follow-up. The
two main questionswe soughtto answer were whether
fluoroscopically guided trochanteric bursa injections
were superior to “blinded” injections and whether
intra-bursal injections were better than extra-bursal
injections.
Theprimaryoutcomemeasureswerepainscoreson
a 0-10 numerical rating scale at rest and with activity
one month post-injection, which reflected the average
pain the patient experienced over the preceding week.
Secondary outcome measures were the SF-36, Oswes-
try disability index, reduction in drug use (predefined
asa 20%reductionin opioiduseor completecessation
of a non-opioid analgesic),
29 global perceived effect,
and a composite “successful outcome.” The SF-36 is a
wellvalidatedinstrumentusedtomeasuretheeffectsof
medical conditions on eight health related domains
believed to be universally important, which are not
specific to age, treatment, or disease.
30 The Oswestry
disability index is a well validated instrumented
designed to assess functional limitations secondary to
legorbackpain.
31Ingeneral,scoresonthisindexof0-
20 indicate minimal disability, 21-40 indicates moder-
atedisability,and41-60indicatesseveredisability.We
defined a positive global perceived effect as a positive
response to all three of “My pain has improved/wor-
sened/stayed the same since my last visit,”“ The treat-
ment I received improved/did not improve my ability
to perform daily activities,” and “I am satisfied/not
Table 2 |Baseline demographic and clinical characteristics by injection method. Values are
numbers (percentages) unless stated otherwise
Characteristics
Blind
(n=33)
Fluoroscopically guided
(n=32) P value
Mean (SD, range) age (years) 56.1 (15.5, 21.0-
85.0)
54.3 (13.3, 30.0-76.0) 0.62
Female sex 28 (85) 28 (88) 1.0
Obesity 8 (24) 9 (28) 0.72
Mean (SD, range) duration of pain
(years)
4.4 (3.9, 0.1-16.0) 3.3 (3.4, 0.2-13.0) 0.23
Opioid use 12 (36) 10 (31) 0.66
Mean (SD, range) Oswestry
disability index score
42.2 (12.6, 16.0-
64.0)
38.6 (14.9, 14.0-67.0) 0.30
Mean (SD, range) pain intensity at
rest*
4.6 (2.6, 1.0-10.0) 5.1 (2.6, 1.0-10.0) 0.43
Mean (SD, range) pain intensity
with activity*
7.2 (2.0, 2.0-10.0) 7.8 (2.2, 2.0-10.0) 0.32
Treatment centre:
0.24
Johns Hopkins Medical Center 17 (52) 19 (59)
Walter Reed Army Medical
Center
9 (27) 11 (34)
Landstuhl Regional Medical
Center
7 (21) 2 (6)
*Numerical rating pain scale.
Table 3 |SF-36 scale scores by injection method. Values are mean (SD, range) unless stated otherwise
Scale
Baseline Month 1 Month 3
1998 US
norms*
Blind
(n=33)
Fluoroscopically
guided (n=32) P value
Blind
(n=32)
Fluoroscopically
guided (n=30) P value
Blind
(n=20)
Fluoroscopically
guided (n=15) P value
Physical
functioning
36.1 (24.5,
0.0-95.0)
33.1 (22.7, 5.0-
75.0)
0.62 43.6 (21.8,
5.0-95.0)
45.2 (29.9, 5.0-
95.0)
0.81 44.5 (22.0,
5.0-90.0)
45.7 (26.7, 5.0-
90.0)
0.89 83.0
Physical roles 25.0 (38.5,
0.0-100.0)
18.8 (29.1, 0.0-
100.0)
0.46 37.5 (42.1,
0.0-100.0)
38.3 (43.9, 0.0-
100.0)
0.94 35.0 (39.2,
0.0-100.0)
28.3 (37.6, 0.0-
100.0)
0.61 77.9
Bodily pain 40.5 (16.8,
10.0-77.5)
35.7 (20.0, 0.0-
77.5)
0.31 55.5 (19.3,
10.0-90.0)
58.3 (21.5, 32.5-
100.0)
0.58 48.3 (19.0,
10.0-90.0)
48.5 (22.7, 22.5-
90.0)
0.97 70.2
General health 63.8 (13.3,
35.0-92.0)
55.3 (22.4, 15.0-
97.0)
0.07 67.3 (17.1,
30.0-92.0)
58.1 (25.0, 20.0-
100.0)
0.10 65.6 (18.6,
20.0-97.0)
59.7 (19.6, 25.0-
87.0)
0.37 70.1
Vitality 40.6 (20.9,
10.0-80.0)
39.1 (18.7, 0.0-
75.0)
0.75 50.9 (18.5,
0.0-80.0)
44.7 (25.3, 5.0-
85.0)
0.27 49.8 (20.0,
20.0-80.0)
41.0 (19.0, 5.0-
80.0)
0.20 57.0
Social
functioning
61.7 (22.1,
25.0-100.0)
52.3 (26.6, 0.0-
100.0)
0.13 69.9 (21.7,
25.0-100.0)
64.2 (26.2, 12.5-
100.0)
0.35 66.9 (27.3,
25.0-100.0)
62.5 (23.1, 25.0-
100.0)
0.61 83.6
Emotional roles 52.5 (42.5,
0.0-100.0)
54.2 (44.6, 0.0-
100.0)
0.88 69.8 (37.3,
0.0-100.0)
56.7 (45.6, 0.0-
100.0)
0.22 71.7 (34.7,
0.0-100.0)
53.3 (39.4, 0.0-
100.0)
0.16 83.1
Mental health 70.9 (16.6,
32.0-96.0)
68.0 (19.3, 24.0-
100.0)
0.52 76.0 (15.2,
48.0-100.0)
65.5 (20.8, 24.0-
92.0)
0.03 73.6 (16.2,
40.0-96.0)
65.3 (23.4, 20.0-
92.0)
0.25 75.2
*SF-36 normative data for US general population in 1998. Available at www.sf-36.org/cgi-bin/nbscalc/nbs2.cgi?
PF=100&RP=100&BP=100&GH=100&VT=100&SF=100&RE=100&MH=100&CC=us2.
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recommend it to others.”
We designated the composite binary variable “suc-
cessful outcome” before the start of the study as a
reduction of at least 50% in numerical rating scale
pain score either at rest or with activity and a positive
global perceived effect obviating the need for further
interventions. In addition to outcome measures, other
variables analysed were age, sex, whether the injectate
was intra-bursal or extra-bursal, duration of pain,
opioid usage, adequacy of blinding, accuracy of injec-
tion, and obesity (body mass index ≥30).
We used Stata MP 10.1 for statistical analyses. We
present normally distributed data as means and stan-
dard deviations. We assessed statistical significance by
using t tests for continuous, normally distributed vari-
ables; the Wilcoxon sign rank test for non-normally
distributed, paired data; and Pearson’s χ
2 and Fisher’s
exacttestsforcategoricalvariables.WeconsideredaP
value <0.05 to be statistically significant.
RESULTS
The figure shows the flow of participants through the
study. Tables 1 and 2 show demographic data for par-
ticipants in each study centre and by method of injec-
tion. Overall, neither baseline differences between
study centres nor those between injection method
groupswerestatisticallysignificant,indicatingthatran-
domisationwassuccessful.Mostpatientswerewomen,
in their mid-50s, not obese, and not using opioid
analgesics, although patients at Landstuhl Regional
Medical Center were substantially younger than
those at the other sites, which reflects the nature of
the beneficiaries of the US Department of Defense
treated there. Patients randomised to receive a blind
injection reported a mean duration of pain of
4.4years,whereasthoseallocatedtoreceivefluorosco-
picallyguidedinjectionshadhadpainforanaverageof
3.3 years. Average pain intensity at rest was moderate,
but it increased to severe with activity. Baseline ability
to function was severely limited in the blind injection
group and moderately limited in the fluoroscopic
group, although the between group differences were
small.
Inthefluoroscopygroup,12of32injectionsentered
thebursaonthefirstattemptcomparedwith12of33in
the landmark guided treatment group, for an overall
accuracy rate of 37%. In the overall cohort, 39 (61%)
of the 64 patients experienced a positive categorical
outcome (≥50% pain relief and satisfaction with the
results) at one month and therefore remained in the
studyfortheirthreemonthfollow-up.Atthreemonths,
28 (44%) participants continued to report substantial
Table 4 |Clinical and demographic characteristics stratified by success at three months
(n=64). Values are numbers (percentages) unless stated otherwise
Characteristics Not successful (n=36) Successful (n=28) P value
Mean (SD, range) age (years) 55.9 (14.4, 22-79) 54.6 (14.8, 21-85) 0.74
Female sex 30 (83) 25 (89) 0.72
Obesity 11 (31) 6 (21) 0.57
Mean (SD, range) duration of pain
(years)
2.7 (2.4, 0.1-9.0) 5.4 (4.5, 0.3-16.0) 0.40
Opioid use 12 (33) 9 (32) 0.92
Mean (SD, range) Oswestry disability
index (pre-procedure)
42.8 (12.6, 14-67) 36.6 (14.3, 14-60) 0.46
Mean (SD, range) baseline pain
intensity at rest*
4.8 (2.6, 1-10) 4.7 (2.6, 1-10) 0.26
Mean (SD, range) baseline pain
intensity with activity*
7.5 (1.8, 3-10) 7.5 (2.4, 2-10) 0.46
*Numerical rating pain scale.
Table 5 |Outcomes stratified by injection method. Values are numbers (percentages) unless stated otherwise
Outcome Blind Fluoroscopically guided P value
Overall success: (n=32) (n=32)
0.38
None 10 (31) 15 (47)
At 1 month only 7 (22) 4 (13)
At 3 months 15 (47) 13 (41)
Mean (SD, range) pain intensity* at 1 month: (n=32) (n=32)
Rest 2.2 (2.4, 0-10) 2.7 (2.5, 0-9) 0.41
Activity 4.0 (2.6, 0-10) 5.0 (2.9, 0-10) 0.16
Mean (SD, range) pain intensity* at 3 months: (n=22) (n=16)
Rest 2.6 (2.5, 0-7.5) 1.9 (1.7, 0-6) 0.34
Activity 4.8 (2.6, 0-10.0) 4.7 (2.8, 0-10) 0.90
Mean (SD, range) Oswestry disability index at 1 month† 32.1 (15.2, 0-60) 32.3 (17.4, 0-66) 0.96
Mean (SD, range) Oswestry disability index at 3 months† 31.7 (15.1, 6-64) 33.6 (13.6, 14-60) 0.69
Positive global perceived effect at 3 months‡:( n =32) (n=32)
0.80 No 15 (47) 16 (50)
Yes 17 (53) 16 (50)
Reduction in drug use at 3 months: (n=19) (n=15)
0.60 No 11 (58) 10 (67)
Yes 8 (42) 5 (33)
*Numerical rating pain scale.
†Lower Oswestry disability index indicates better functioning.
‡Failed treatment at one month carried over as negative global perceived effect at three months.
RESEARCH
page 4 of 7 BMJ | ONLINE FIRST | bmj.comrelief coupled with a positive global perceived effect;
we found no significant differences between treatment
groups.
Table 3 shows scores for each of the SF-36 scales
stratified by injection method. The only statistically
significant difference was in the mental health scale at
theonemonthfollow-up;patientswhoreceivedablind
injection reported slightly better scores. Other differ-
ences tended to be in favour of the blind injection
group, with the exception of emotional roles at base-
line, physical roles and bodily pain at one month, and
physical functioning at three months.
Whenexaminedbysuccessatthreemonths,theclin-
icalanddemographiccharacteristicsofthestudyparti-
cipants were similar (table 4). Despite the lack of
statistical significance, an unsuccessful treatment at
three months was more common among men, obese
people, patients with shorter duration of pain, and
those with greater disability on the Oswestry disability
index.
We examined outcomes by injection method, num-
ber of injections (data not shown), and whether the
injection was intra-bursal or extra-bursal (tables 5
and 6). For the primary outcome measure, numerical
rating scale score at one month, the mean hip pain
score at rest declined from 5.1 to 2.7 (P=0.0001) in
the fluoroscopically guided injection group and from
4.6to2.2(P=0.0001)intheblindinjectiongroup.With
respect to activity related pain intensity, scores in the
fluoroscopy group fell from 7.8 to 5.0 (P<0.0001) at
one month, which was comparable to the improve-
ment found in the blind injection group (decrease
from 7.2 to 4.0; P<0.0001). Other differences between
the injection method groups also failed to reach statis-
tical significance, apart from a greater decrease in dis-
ability among patients who received blind injections.
However, we notedtrends for greater improvementin
pain at rest at three months in the fluoroscopy group
andapositiveglobalperceivedeffectintheblindinjec-
tion group.
When stratified by the number of injections—one
injection (all blind injections plus intra-bursal on first
attempt in fluoroscopy group) versus more than one
injection (two or more attempts for intra-bursal spread
in fluoroscopy group)—the outcomes for single and
multipleinjectiongroupswereessentiallycomparable.
Although the decrease in mean Oswestry disability
indexscorewassignificantlygreaterinthesingleinjec-
tiongroup(P=0.003),wefoundagreaterimprovement
in the multiple injection group for the SF-36 general
health subscale (P=0.02).
When examined by location of injection, no signifi-
cant differences existed between the intra-bursal and
extra-bursal groups. However, we noted trends for
greater improvement in pain at rest at three months
and the SF-36 general health category for intra-bursal
injections,andfordrugreductionandtheSF-36vitality
index for extra-bursal spread of contrast.
Atthetimeofdischarge,blindingwasassessedbyan
independent evaluator who asked patients which
Table 6 |Outcomes stratified by injection location. Values are numbers (percentages) unless stated otherwise
Outcome
Intra-bursal (all fluoroscopically
guided injections plus blind
injections into bursa)
Extra-bursal (blind injections not in
bursa) P value
Overall success: (n=43) (n=20)
0.72
None 18 (42) 6 (30)
At 1 month only 7 (16) 4 (20)
At 3 months 18 (42) 10 (50)
Mean (SD, range) pain intensity* at
1 month:
(n=43) (n=20)
Rest 2.6 (2.4, 0-9) 2.2 (2.6, 0-10) 0.54
Activity 4.7 (2.9, 0-10) 4.3 (2.6, 0-10) 0.62
Mean (SD, range) pain intensity* at
3 months:
(n=24) (n=14)
Rest 2.0 (1.8, 0-6) 2.8 (2.8, 0-7.5) 0.32
Activity 4.6 (2.8, 0-10) 4.9 (2.6, 1-10) 0.82
Mean (SD, range) Oswestry disability
index at 1 month†
29.7 (17.4, 0-66, n=43) 37.8 (12.4, 18-60, n=20) 0.07
Mean (SD, range) Oswestry disability
index at 3 months†
31.2 (13.0, 9-60, n=24) 34.8 (16.6, 6-64) 0.46
Positive global perceived effect at
3 months:‡
(n=43) (n=20)
0.78 No 21 (49) 9 (45)
Yes 22 (51) 11 (55)
Drug reduction at 3 months: (n=22) (n=12)
0.14 No 16 (73) 5 (42)
Yes 6 (27) 7 (58)
*Numerical rating pain scale.
†Lower Oswestry disability index indicates better functioning.
‡Failed treatment at one month carried over as negative global perceived effect at three months.
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56 patients who could give an answer, 23 guessed cor-
rectly, indicating adequacy of blinding. No complica-
tions were noted in any patient.
DISCUSSION
Theprincipalfindingofthisstudysuggeststhattheuse
of fluoroscopy does not improve outcomes in patients
with greater trochanteric pain syndrome who receive
corticosteroid injections. This is consistent with our
secondary finding showing comparable success rates
for intra-bursaland extra-bursalinjections.The results
fromthispilotstudyshouldnotbesurprisingconsider-
ing that most patients clinically diagnosed as having
greater trochanteric pain syndrome have no radio-
logical evidence of bursal inflammation.
2425 Even
among patients with actual “trochanteric bursitis,”
many develop secondary pathology in adjacent
tissues.
5 In thesepatients, usingradiographicguidance
to direct the needle into the bursa in patients with an
extra-bursal pain generator might be counterproduc-
tive. However, subgroup analysis did not reveal any
significant differences in outcomes in fluoroscopy
patients who needed more than one needle placement
beforeinjection(45%successrateatthreemonths)and
patientsinwhomonlyoneinjectionattemptwasmade
(44% success rate).
Our results suggest that referral to a pain specialist
with fluoroscopic capability is not warranted in most
patients with greater trochanteric pain syndrome who
present to a primary care doctor, physiatrist, or sur-
geon, all of whom often encounter this condition.
Thedelayintreatmententailedbyreferraltoasubspe-
cialty may even be detrimental, as previous inter-
ventional studies have found an inverse relation
between duration of pain and likelihood of
success.
26-28 Patients who fail “blind” trochanteric
bursa injections and those with radiological evidence
of bursal inflammation, however, may benefit from
referral to a pain treatment centre, as this study (37%
accuracyrate)andapreviousonefoundthatinjections
guided by landmarks alone are unlikely to diffuse into
thebursa.
23Onthebasisofcurrentthirdpartyreimbur-
sement codes for the 10 most recent procedures done
at Johns Hopkins, the cost for a subspecialty consulta-
tion and subsequent procedure using fluoroscopy
(including facility fees) is $1216 (£843; €897),
compared with $188 if the procedure is done during
an office visit.
An examination of the relative strengths and weak-
nesses of this study is needed to put the results in con-
text. Firstly, this is the only controlled study that has
evaluatedtrochantericbursainjections.Theabsenceof
controlled studies is somewhat surprising, considering
thatarecentauditfoundthatthenumberofprocedures
billed to Medicare, the largest health insurance sup-
plierintheUnitedStates,underthecurrentprocedural
terminology code pertaining to “major joint or bursa
injection,” which includes trochanteric bursa injec-
tions, far exceeds that of any other pain management
intervention.
32 Secondly, our outcomes are less posi-
tivethanseveralothersreportedfortrochantericbursa
injections.
1011However,allpreviousstudiesevaluating
trochanteric bursa injections were unblinded and
uncontrolled, which tends to accentuate expectation
bias. Nevertheless, larger, placebo controlled studies
are needed to better ascertain the efficacy of trochan-
teric bursa corticosteroid injections.
Anotherconcernaboutthisstudystemsfromthefact
that only 39 of the 65 participants had outcome data
recorded at three months. This was justified on the
basis of ethical concerns stemming from pilot data
showing that less than 10% of patients with “negative”
outcomes at one month would experience a “positive”
outcome three months post-injection with no inter-
vening treatment. However, not carrying over one
month treatment failures limits the long term conclu-
sions on efficacy and differences between treatment
groups that can be reached from these results.
The implications of this study may also extend
beyond the sphere of “hip pathology,” as they suggest
that more sophisticated and expensive treatments do
notnecessarilytranslateintohigherqualitycareorbet-
ter outcomes. As an example, we need only examine
the historical record of treatment for back pain, where
rapidly evolving technological advances have not
resultedin paralleldeclines inprevalenceor indisabil-
ity claims.
33
Conclusions
Fluoroscopically guided trochanteric bursa injections
were not associated with superior outcomes to injec-
tions guided by landmarks alone in patients who pre-
sented with clinical greater trochanteric pain
syndrome. Referral to a pain treatment centre should
be reserved for patients with greater trochanteric pain
syndrome who fail landmark guided injections and
conservative treatment. Because a single study of this
size is not sufficient to change practice, further studies
are neededbothto confirmthe efficacy of trochanteric
bursa injections in greater trochanteric pain syndrome
andtodeterminewhichpatientsmaybenefitfromeach
approach.
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